Zydus Cadila receives USFDA approval for two products

Zydus Cadila has received final approval from THE USFDA to markets lsosorbide Dinitrate Tablets USP (US RLD - Isordil Tablet), in the strengths of 5 mg, 10 mg, 20 mg, 30 mg, and 40 mg, and also for Desonide Cream (US RLD - Desonide Cream), 0.05%.
 
lsosorbide Dinitrate Tablets USP (US RLD - Isordil Tablet) in the strengths of 5 mg, 10 mg, 20 mg, 30 mg, and 40 mg is used for preventing attacks of chest pain (angina). lt widens blood vessels, making it easier for blood to flow through them and for the heart to pump. It will be manufactured at the group’s formulations manufacturing facility, located at Baddi.
 
Desonide Cream (US RLD — Desonide Cream), 0.05% is a mild corticosteroid, which is used to treat a variety of skin conditions, such as rash to reduce swelling, itching, and redness that can occur due to conditions like eczema, dermatitis, allergies, etc. It will be manufactured at the group’s topical manufacturing facility, located at Ahmedabad.
 
Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. Currently, the group has 278 approvals and has filed over 330 ANDAs since the commencement of the filing process from FY03-04.
 
On Friday, the stock of Cadila Healthcare Ltd. closed at Rs. 251.05, down by 1.24 per cent or Rs. 3.15 per share. The 52-week high is Rs. 370 and 52-week low is Rs. 206.45 on BSE.